19 results on '"Marquié, Marta"'
Search Results
2. Unveiling the sound of the cognitive status: Machine Learning-based speech analysis in the Alzheimer’s disease spectrum
- Author
-
García-Gutiérrez, Fernando, Alegret, Montserrat, Marquié, Marta, Muñoz, Nathalia, Ortega, Gemma, Cano, Amanda, De Rojas, Itziar, García-González, Pablo, Olivé, Clàudia, Puerta, Raquel, García-Sanchez, Ainhoa, Capdevila-Bayo, María, Montrreal, Laura, Pytel, Vanesa, Rosende-Roca, Maitee, Zaldua, Carla, Gabirondo, Peru, Tárraga, Lluís, Ruiz, Agustín, Boada, Mercè, and Valero, Sergi
- Published
- 2024
- Full Text
- View/download PDF
3. Exploring small non-coding RNAs as blood-based biomarkers to predict Alzheimer’s disease
- Author
-
Gutierrez-Tordera, Laia, Papandreou, Christopher, Novau-Ferré, Nil, García-González, Pablo, Rojas, Melina, Marquié, Marta, Chapado, Luis A., Papagiannopoulos, Christos, Fernàndez-Castillo, Noèlia, Valero, Sergi, Folch, Jaume, Ettcheto, Miren, Camins, Antoni, Boada, Mercè, Ruiz, Agustín, and Bulló, Mònica
- Published
- 2024
- Full Text
- View/download PDF
4. The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
- Author
-
Rosende-Roca, Maitee, Abdelnour, Carla, Esteban, Ester, Tartari, Juan Pablo, Alarcon, Emilio, Martínez-Atienza, Juliana, González-Pérez, Antonio, Sáez, María E., Lafuente, Asunción, Buendía, Mar, Pancho, Ana, Aguilera, Nuria, Ibarria, Marta, Diego, Susana, Jofresa, Sara, Hernández, Isabel, López, Rogelio, Gurruchaga, Miren Jone, Tárraga, Lluís, Valero, Sergi, Ruiz, Agustín, Marquié, Marta, and Boada, Mercè
- Published
- 2021
- Full Text
- View/download PDF
5. Early detection of amyloid load using 18F-florbetaben PET
- Author
-
Bullich, Santiago, Roé-Vellvé, Núria, Marquié, Marta, Landau, Susan M., Barthel, Henryk, Villemagne, Victor L., Sanabria, Ángela, Tartari, Juan Pablo, Sotolongo-Grau, Oscar, Doré, Vincent, Koglin, Norman, Müller, Andre, Perrotin, Audrey, Jovalekic, Aleksandar, De Santi, Susan, Tárraga, Lluís, Stephens, Andrew W., Rowe, Christopher C., Sabri, Osama, Seibyl, John P., and Boada, Mercè
- Published
- 2021
- Full Text
- View/download PDF
6. Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment.
- Author
-
García-Gutiérrez, Fernando, Marquié, Marta, Muñoz, Nathalia, Alegret, Montserrat, Cano, Amanda, de Rojas, Itziar, García-González, Pablo, Olivé, Clàudia, Puerta, Raquel, Orellana, Adelina, Montrreal, Laura, Pytel, Vanesa, Ricciardi, Mario, Zaldua, Carla, Gabirondo, Peru, Hinzen, Wolfram, Lleonart, Núria, García-Sánchez, Ainhoa, Tárraga, Lluís, and Ruiz, Agustín
- Subjects
AMYLOID ,MACHINE learning ,SPEECH ,VOICE analysis ,ALZHEIMER'S disease ,MILD cognitive impairment - Abstract
Alzheimer's disease (AD) is a neurodegenerative condition characterized by a gradual decline in cognitive functions. Currently, there are no effective treatments for AD, underscoring the importance of identifying individuals in the preclinical stages of mild cognitive impairment (MCI) to enable early interventions. Among the neuropathological events associated with the onset of the disease is the accumulation of amyloid protein in the brain, which correlates with decreased levels of Aβ42 peptide in the cerebrospinal fluid (CSF). Consequently, the development of non-invasive, low-cost, and easy-to-administer proxies for detecting Aβ42 positivity in CSF becomes particularly valuable. A promising approach to achieve this is spontaneous speech analysis, which combined with machine learning (ML) techniques, has proven highly useful in AD. In this study, we examined the relationship between amyloid status in CSF and acoustic features derived from the description of the Cookie Theft picture in MCI patients from a memory clinic. The cohort consisted of fifty-two patients with MCI (mean age 73 years, 65% female, and 57% positive amyloid status). Eighty-eight acoustic parameters were extracted from voice recordings using the extended Geneva Minimalistic Acoustic Parameter Set (eGeMAPS), and several ML models were used to classify the amyloid status. Furthermore, interpretability techniques were employed to examine the influence of input variables on the determination of amyloid-positive status. The best model, based on acoustic variables, achieved an accuracy of 75% with an area under the curve (AUC) of 0.79 in the prediction of amyloid status evaluated by bootstrapping and Leave-One-Out Cross Validation (LOOCV), outperforming conventional neuropsychological tests (AUC = 0.66). Our results showed that the automated analysis of voice recordings derived from spontaneous speech tests offers valuable insights into AD biomarkers during the preclinical stages. These findings introduce novel possibilities for the use of digital biomarkers to identify subjects at high risk of developing AD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress.
- Author
-
Morató, Xavier, Marquié, Marta, Tartari, Juan Pablo, Lafuente, Asunción, Abdelnour, Carla, Alegret, Montserrat, Jofresa, Sara, Buendía, Mar, Pancho, Ana, Aguilera, Núria, Ibarria, Marta, Diego, Susana, Cuevas, Rosario, Cañada, Laia, Calvet, Anna, Antonio, Ester Esteban-De, Pérez-Cordón, Alba, Sanabria, Ángela, de Rojas, Itziar, and Nuñez-Llaves, Raúl
- Subjects
- *
MILD cognitive impairment , *OXIDATIVE stress , *CLINICAL trials , *ALZHEIMER'S disease , *MINI-Mental State Examination , *SUMATRIPTAN , *NEUROFIBRILLARY tangles - Abstract
Although beta-amyloid (Aβ) and phosphorylated tau remain the preferred targets for disease-modifying treatments (DMT) against Alzheimer's disease (AD), part of the pathophysiological mechanisms of cognitive impairment are related to neuroinflammation and oxidative stress. In mild cognitive impairment (MCI), a prodromal stage of AD and other neurodegenerative conditions, the joint appearance of inflammation, oxidative stress, and metabolic alterations are the common pathways of neurotoxicity and neurodegeneration. The standardized extract of Ginkgo biloba EGb 761 interferes with the pathogenic mechanisms involved in both the development of cognitive impairment due to AD and that of vascular origin. The primary objective of this study is to compare changes in the levels of blood markers of inflammation and oxidative stress after treatment with EGb 761 in a cohort of 100 patients with MCI. In addition, we aim to assess changes in these blood markers during an additional 12-month extension phase in which patients in the control group will also receive EGb 761 and patients in the active group will extend their treatment duration. Secondary objectives include comparing changes in neuropsychiatric and cognitive test scores between the baseline (v0) and 12-month visits (v2). This study is a Phase IV, single-center, randomized, open-label, parallel-group clinical trial consisting of the 12-month follow-up of a cohort of participants with MCI [Global Deterioration Scale (GDS) = 3] and an extension with an additional 12-month follow-up. During the first 12 months, participants will be randomized into two arms: in one arm, patients will receive 1 daily tablet of EGb 761 240 mg orally (study group, n = 50), while in the other arm, patients will not receive EGb 761 and will undergo the same assessments as the treated group (control group, n = 50). After the first 12 months of the study, patients in the EGb 761-treated group will continue treatment, and patients in the control group will be offered one EGb 761 240 mg tablet per day orally. All participants will be monitored for an additional 12 months. A battery of blood markers of inflammation and oxidative stress will be quantified at v0, v1, v2, v3, and v4. The Olink Proteomics panel of inflammation markers (https://www.olink.com/products/inflammation/) will be used to evaluate 92 proteins associated with inflammatory diseases and related biological processes. The second panel measures 92 proteins involved in neurological processes. At v0, v2, and v4, neuropsychological and neurological evaluations will be conducted in addition to vital signs and anthropometric studies using a body composition monitor with bioimpedance technology (Tanita). Sixty percent of the 100 MCI patients recruited were women. The mean age was 73.1 years, and the mean time between symptom onset and MCI diagnosis was 2.9 years. The mean Mini-Mental State Examination (MMSE) score was 26.7. Depressive and anxiety disorders, as well as vascular risk factors, were the most frequent comorbidities among the cohort. The study is still ongoing, and results for the first year of treatment (v0, v1, v2) are expected by 2023. Individuals with MCI have an elevated risk of developing dementia. EGb 761 is used worldwide for the symptomatic treatment of cognitive disorders due to its neuroprotective effects. In experimental models and clinical observational studies, EGb 761 has shown strong antioxidant and anti-inflammatory activity. As a result, this study has been proposed to evaluate the antioxidant and anti-inflammatory effects on plasma markers and their potential clinical correlation with the progression of cognitive decline in patients with MCI. Trial registration: Registro Español de estudios clínicos (REec) number 2020-003776-41, ClinicalTrials.gov Identifier: NCT05594355. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer's disease in individuals with mild cognitive impairment: The NORFACE cohort.
- Author
-
Marquié, Marta, García-Sánchez, Ainhoa, Alarcón-Martín, Emilio, Martínez, Joan, Castilla-Martí, Miguel, Castilla-Martí, Luis, Orellana, Adelina, Montrreal, Laura, de Rojas, Itziar, García-González, Pablo, Puerta, Raquel, Olivé, Clàudia, Cano, Amanda, Hernández, Isabel, Rosende-Roca, Maitée, Vargas, Liliana, Tartri, Juan Pablo, Antonio, Ester Esteban-De, Bojaryn, Urszula, and Ricciardi, Mario
- Subjects
MILD cognitive impairment ,ALZHEIMER'S disease ,CEREBROSPINAL fluid ,OPTICAL coherence tomography ,CHRONIC obstructive pulmonary disease - Abstract
Background: Optical coherence tomography angiography (OCT-A) is a novel method in the dementia field that allows the detection of retinal vascular changes. The comparison of OCT-A measures with established Alzheimer's disease (AD)-related biomarkers is essential to validate the former as a marker of cerebrovascular impairment in the AD continuum. We aimed to investigate the association of macular vessel density (VD) in the superficial plexus quantified by OCT-A with the AT(N) classification based on cerebrospinal fluid (CSF) Ab1-42, p181-tau and t-tau measurements in individuals with mild cognitive impairment (MCI). Materials and methods: Clinical, demographic, ophthalmological, OCT-A and CSF core biomarkers for AD data from the Neuro-ophthalmology Research at Fundació ACE (NORFACE) project were analyzed. Differences in macular VD in four quadrants (superior, nasal, inferior, and temporal) among three AT(N) groups [Normal, Alzheimer and Suspected non-Alzheimer pathology (SNAP)] were assessed in a multivariate regression model, adjusted for age, APOE +4 status, hypertension, diabetes mellitus, dyslipidemia, heart disease, chronic obstructive pulmonary disease and smoking habit, using the Normal AT(N) group as the reference category. Results: The study cohort comprised 144 MCI participants: 66 Normal AT(N), 45 Alzheimer AT(N) and 33 SNAP AT(N). Regression analysis showed no significant association of the AT(N) groups with any of the regional macular VD measures (all, p > 0.16). The interaction between sex and AT(N) groups had no effect on differentiating VD. Lastly, CSF Aβ1-42, p181-tau and t-tau measures were not correlated to VD (all r < 0.13; p > 0.13). Discussion: Our study showed that macular VD measures were not associated with the AT(N) classification based on CSF biomarkers in patients with MCI, and did not differ between AD and other underlying causes of cognitive decline in our cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment.
- Author
-
Marquié, Marta, García-Gutiérrez, Fernando, Orellana, Adelina, Montrreal, Laura, de Rojas, Itziar, García-González, Pablo, Puerta, Raquel, Olivé, Clàudia, Cano, Amanda, Hernández, Isabel, Rosende-Roca, Maitée, Vargas, Liliana, Tartari, Juan Pablo, Esteban-De Antonio, Ester, Bojaryn, Urszula, Ricciardi, Mario, Ariton, Diana M., Pytel, Vanesa, Alegret, Montserrat, and Ortega, Gemma
- Subjects
- *
MILD cognitive impairment , *DISEASE risk factors , *DEMENTIA patients , *ALZHEIMER'S disease , *MENTAL depression , *CEREBROSPINAL fluid - Abstract
Few studies have addressed the impact of the association between Alzheimer's disease (AD) biomarkers and NPSs in the conversion to dementia in patients with mild cognitive impairment (MCI), and no studies have been conducted on the interaction effect of these two risk factors. AT(N) profiles were created using AD-core biomarkers quantified in cerebrospinal fluid (CSF) (normal, brain amyloidosis, suspected non-Alzheimer pathology (SNAP) and prodromal AD). NPSs were assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). A total of 500 individuals with MCI were followed-up yearly in a memory unit. Cox regression analysis was used to determine risk of conversion, considering additive and multiplicative interactions between AT(N) profile and NPSs on the conversion to dementia. A total of 224 participants (44.8%) converted to dementia during the 2-year follow-up study. Pathologic AT(N) groups (brain amyloidosis, prodromal AD and SNAP) and the presence of depression and apathy were associated with a higher risk of conversion to dementia. The additive combination of the AT(N) profile with depression exacerbates the risk of conversion to dementia. A synergic effect of prodromal AD profile with depressive symptoms is evidenced, identifying the most exposed individuals to conversion among MCI patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
- Author
-
Pascual-Lucas, María, Allué, José Antonio, Sarasa, Leticia, Fandos, Noelia, Castillo, Sergio, Terencio, Jose, Sarasa, Manuel, Tartari, Juan Pablo, Sanabria, Ángela, Tárraga, Lluís, Ruíz, Agustín, Marquié, Marta, Seo, Sang Won, Jang, Hyemin, Boada, Mercè, on behalf of the FACEHBI study group, Aguilera, N., Alarcón-Martín, E., Alegret, M., and Alonso-Lana, S.
- Subjects
ALZHEIMER'S disease ,COGNITION disorders ,RECEIVER operating characteristic curves ,EPISODIC memory ,CEREBRAL atrophy ,PATHOLOGICAL physiology ,MILD cognitive impairment - Abstract
Background: Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer's disease (AD). In this study, we investigated the ability of plasma amyloid-beta (Aβ)42/Aβ40 ratio measured by an antibody-free mass-spectrometric (MS) method, ABtest-MS, to detect early pathological changes of AD. Methods: This cohort study included data from the baseline and 2-year follow-up visits from the Fundació ACE Healthy Brain Initiative (FACEHBI) study. Plasma Aβ42/Aβ40 was measured with ABtest-MS and compared to
18 F-Florbetaben PET as the reference standard (cutoff for early amyloid deposition of 13.5 centiloids). Cross-validation was performed in an independent DPUK-Korean cohort. Additionally, associations of plasma Aβ42/Aβ40 with episodic memory performance and brain atrophy were assessed. Results: The FACEHBI cohort at baseline included 200 healthy individuals with subjective cognitive decline (SCD), of which 36 (18%) were Aβ-PET positive. Plasma Aβ42/Aβ40 levels were significantly lower in Aβ-PET positive individuals (median [interquartile range, IQR], 0.215 [0.203–0.236]) versus Aβ-PET negative subjects (median [IQR], 0.261 [0.244–0.279]) (P <.001). Plasma Aβ42/Aβ40 was significantly correlated with Aβ-PET levels (rho = −0.390; P <.001) and identified Aβ-PET status with an area under the receiver operating characteristic curve (AUC) of 0.87 (95% confidence interval [CI], 0.80–0.93). A cutoff for the Aβ42/Aβ40 ratio of 0.241 (maximum Youden index) yielded a sensitivity of 86.1% and a specificity of 80.5%. These findings were cross-validated in an independent DPUK-Korean cohort (AUC 0.86 [95% CI 0.77–0.95]). Lower plasma Aβ42/Aβ40 ratio was associated with worse episodic memory performance and increased brain atrophy. Plasma Aβ42/Aβ40 at baseline predicted clinical conversion to mild cognitive impairment and longitudinal changes in amyloid deposition and brain atrophy at 2-year follow-up. Conclusions: This study suggests that plasma Aβ42/Aβ40, as determined by this MS-based assay, has potential value as an accurate and cost-effective tool to identify individuals in the earliest stages of AD, supporting its implementation in clinical trials, preventative strategies and clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
11. Differences in macular vessel density in the superficial plexus across cognitive impairment: the NORFACE cohort.
- Author
-
Marquié, Marta, Valero, Sergi, Martínez, Joan, Alarcón-Martín, Emilio, García-Sánchez, Ainhoa, de Rojas, Itziar, Castilla-Martí, Miguel, Castilla-Martí, Luis, Hernández, Isabel, Rosende-Roca, Maitée, Vargas, Liliana, Tartari, Juan Pablo, Esteban-De Antonio, Ester, Bojaryn, Urszula, Pytel, Vanesa, Narvaiza, Leire, Alegret, Montserrat, Ortega, Gemma, Espinosa, Ana, and Sanabria, Ángela
- Subjects
- *
COGNITION disorders , *ALZHEIMER'S disease , *MILD cognitive impairment , *OPTICAL coherence tomography , *MINI-Mental State Examination - Abstract
Optical coherence tomography angiography (OCT-A) allows the detection of retinal vessel density (VD) loss, which is a reflection of brain vascular pathology. We aimed to investigate differences in macular VD in the superficial plexus in a large cohort of individuals cognitively unimpaired (CU), with mild cognitive impairment due to Alzheimer´s disease (MCI-AD), MCI due to cerebrovascular pathology (MCI-Va), probable Alzheimer´s disease dementia (ADD) and Vascular Dementia (VaD). Clinical, demographical, ophthalmological and OCT-A data from the Neuro-ophthalmology Research at Fundació ACE (NORFACE) project were analyzed. Differences of macular VD in four quadrants (superior, nasal, inferior and temporal) among the five diagnostic groups were assessed in a multivariate regression model, adjusted by age, sex, education, hypertension, diabetes mellitus, heart disease and stroke. The study cohort comprised 672 participants: 128 CU, 120 MCI-AD, 111 MCI-Va, 257 ADD and 56 VaD. Regression analysis showed a significantly higher VD in the temporal quadrant in MCI-AD compared to CU participants (49.05 ± 4.91 vs 47.27 ± 4.17, p = 0.02, d = 0.40), and a significantly lower VD in the inferior quadrant in MCI-Va compared to CU participants (48.70 ± 6.57 vs 51.27 ± 6.39, p = 0.02, d = 0.40). Individuals with heart disease presented significantly lower VD in the inferior quadrant than those without (p = 0.01). The interaction of sex and diagnosis had no effect in differentiating VD. Mini-Mental State Examination (MMSE) scores were not correlated to VD (all r < 0.16; p > 0.07). In conclusion, our study showed that the MCI-AD and MCI-Va groups had significant differences in macular VD in opposite directions in the temporal and inferior quadrants, respectively, compared to CU participants, suggesting that macular VD might be able to differentiate two pathogenic pathways (AD- and cerebrovascular-related) in early stages of cognitive decline. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort.
- Author
-
Orellana, Adelina, García-González, Pablo, Valero, Sergi, Montrreal, Laura, de Rojas, Itziar, Hernández, Isabel, Rosende-Roca, Maitee, Vargas, Liliana, Tartari, Juan Pablo, Esteban-De Antonio, Ester, Bojaryn, Urszula, Narvaiza, Leire, Alarcón-Martín, Emilio, Alegret, Montserrat, Alcolea, Daniel, Lleó, Alberto, Tárraga, Lluís, Pytel, Vanesa, Cano, Amanda, and Marquié, Marta
- Subjects
ALZHEIMER'S disease ,CEREBROSPINAL fluid examination ,BLAND-Altman plot ,CEREBROSPINAL fluid ,POSITRON emission tomography ,MILD cognitive impairment ,ENZYME-linked immunosorbent assay ,CHEMILUMINESCENCE immunoassay - Abstract
Background: Clinical diagnosis of Alzheimer's disease (AD) increasingly incorporates CSF biomarkers. However, due to the intrinsic variability of the immunodetection techniques used to measure these biomarkers, establishing in-house cutoffs defining the positivity/negativity of CSF biomarkers is recommended. However, the cutoffs currently published are usually reported by using cross-sectional datasets, not providing evidence about its intrinsic prognostic value when applied to real-world memory clinic cases. Methods: We quantified CSF Aβ1-42, Aβ1-40, t-Tau, and p181Tau with standard INNOTEST
® ELISA and Lumipulse G® chemiluminescence enzyme immunoassay (CLEIA) performed on the automated Lumipulse G600II. Determination of cutoffs included patients clinically diagnosed with probable Alzheimer's disease (AD, n = 37) and subjective cognitive decline subjects (SCD, n = 45), cognitively stable for 3 years and with no evidence of brain amyloidosis in 18F-Florbetaben-labeled positron emission tomography (FBB-PET). To compare both methods, a subset of samples for Aβ1-42 (n = 519), t-Tau (n = 399), p181Tau (n = 77), and Aβ1-40 (n = 44) was analyzed. Kappa agreement of single biomarkers and Aβ1-42/Aβ1-40 was evaluated in an independent group of mild cognitive impairment (MCI) and dementia patients (n = 68). Next, established cutoffs were applied to a large real-world cohort of MCI subjects with follow-up data available (n = 647). Results: Cutoff values of Aβ1-42 and t-Tau were higher for CLEIA than for ELISA and similar for p181Tau. Spearman coefficients ranged between 0.81 for Aβ1-40 and 0.96 for p181TAU. Passing–Bablok analysis showed a systematic and proportional difference for all biomarkers but only systematic for Aβ1-40. Bland–Altman analysis showed an average difference between methods in favor of CLEIA. Kappa agreement for single biomarkers was good but lower for the Aβ1-42/Aβ1-40 ratio. Using the calculated cutoffs, we were able to stratify MCI subjects into four AT(N) categories. Kaplan–Meier analyses of AT(N) categories demonstrated gradual and differential dementia conversion rates (p = 9.815−27 ). Multivariate Cox proportional hazard models corroborated these findings, demonstrating that the proposed AT(N) classifier has prognostic value. AT(N) categories are only modestly influenced by other known factors associated with disease progression. Conclusions: We established CLEIA and ELISA internal cutoffs to discriminate AD patients from amyloid-negative SCD individuals. The results obtained by both methods are not interchangeable but show good agreement. CLEIA is a good and faster alternative to manual ELISA for providing AT(N) classification of our patients. AT(N) categories have an impact on disease progression. AT(N) classifiers increase the certainty of the MCI prognosis, which can be instrumental in managing real-world MCI subjects. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment.
- Author
-
Roberto, Natalia, Portella, Maria J., Marquié, Marta, Alegret, Montserrat, Hernández, Isabel, Mauleón, Ana, Rosende-Roca, Maitee, Abdelnour, Carla, Esteban de Antonio, Ester, Tartari, Juan P., Vargas, Liliana, López-Cuevas, Rogelio, Bojaryn, Urszula, Espinosa, Ana, Ortega, Gemma, Pérez-Cordón, Alba, Sanabria, Ángela, Orellana, Adelina, de Rojas, Itziar, and Moreno-Grau, Sonia
- Subjects
COGNITION disorders ,MILD cognitive impairment ,VERBAL learning ,PROGNOSIS ,COGNITIVE ability ,SYMPTOMS - Abstract
Introduction: Mild cognitive impairment is often associated with affective and other neuropsychiatric symptoms (NPS). This co-occurrence might have a relevant impact on disease progression, from MCI to dementia. Objective: The aim of this study was to explore the trajectories of cognitive decline in an MCI sample from a memory clinic, taking into consideration a perspective of isolated cognitive functions and based on NPS clusters, accounting for the different comorbid symptoms collected at their baseline visit. Methods: A total of 2,137 MCI patients were monitored over a 2.4-year period. Four clusters of NPS (i.e., Irritability, Apathy, Anxiety/Depression and Asymptomatic) were used to run linear mixed models to explore the interaction of cluster with time on cognitive trajectories using a comprehensive neuropsychological battery (NBACE) administered at baseline and at the three subsequent follow-ups. Results: A significant interaction between cluster and time in cognitive decline was found when verbal learning and cued-recall were explored (p = 0.002 for both memory functions). For verbal learning, the Irritability cluster had the largest effect size (0.69), whereas the Asymptomatic cluster showed the smallest effect size (0.22). For cued-recall, the Irritability cluster had the largest effect size among groups (0.64), and Anxiety/Depression had the smallest effect size (0.21). Conclusions: In MCI patients, the Irritability and Apathy NPS clusters shared similar patterns of worsening in memory functioning, which could point to these NPS as risk factors of a faster cognitive decline, acting as early prognostic markers and helping in the diagnostic process. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols.
- Author
-
Esteban de Antonio, Ester, Pérez-Cordón, Alba, Gil, Silvia, Orellana, Adelina, Cano, Amanda, Alegret, Montserrat, Espinosa, Ana, Alarcón-Martín, Emilio, Valero, Sergi, Martínez, Joan, de Rojas, Itziar, Sotolongo-Grau, Óscar, Martín, Elvira, Vivas, Assumpta, Gomez-Chiari, Marta, Tejero, Miguel Ángel, Bernuz, Mireia, Tárraga, Lluis, Ruiz, Agustín, and Marquié, Marta
- Subjects
MILD cognitive impairment ,PROGNOSIS ,ALZHEIMER'S disease ,LONGITUDINAL method ,BIOMARKERS ,RESEARCH ,RESEARCH methodology ,COGNITION ,MAGNETIC resonance imaging ,MEDICAL cooperation ,EVALUATION research ,NEUROPSYCHOLOGICAL tests ,COMPARATIVE studies ,PSYCHOLOGICAL tests - Abstract
Background: Mild cognitive impairment (MCI) due to Alzheimer's disease (AD) diagnosis is based on cerebrospinal fluid (CSF) or neuroimaging biomarkers. Currently, non-invasive and inexpensive blood-based biomarkers are being investigated, such as neuronal-derived plasma exosomes (NPEs). Neuroinflammation and early vascular changes have been described in AD pathogenesis and can be traced in plasma and NPEs. However, they have not been studied in early onset MCI (EOMCI).Objective: To describe the rationale, design, and baseline characteristics of the participants from the BIOFACE cohort, a two-year observational study on EOMCI conducted at Fundació ACE. The study goal is to characterize the different phenotypes from a clinical, neuropsychological, and biomarker point of view and to investigate the CSF and plasma proteomics as well as the role of NPEs as early biomarkers of AD.Methods: Participants underwent extended neurological and neuropsychological batteries, multimodal biomarkers including brain MRI, blood, saliva, CSF, anthropometric, and neuro-ophthalmological examinations.Results: Ninety-seven patients with EOMCI were recruited. 59.8%were women. Mean age at symptom onset was 57 years; mean MMSE was 28. First degree and presenile family history of dementia was present in 60.8%and 15.5%, respectively. Depressive and anxiety disorders along with vascular risk factors were the most frequent comorbidities. 29%of participants were APOE ɛ4 carriers, and 67%showed a CSF normal ATN profile.Conclusion: BIOFACE is a two-year study of clinical, cognition, and biomarkers that will shed light on the physiopathology and the potential utility of plasma and NPEs as non-invasive early diagnostic and prognostic biomarkers in people younger than 65 years. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
15. From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery.
- Author
-
Alegret, Montserrat, Espinosa, Ana, Ortega, Gemma, Pérez-Cordón, Alba, Sanabria, Ángela, Hernández, Isabel, Marquié, Marta, Rosende-Roca, Maitée, Mauleón, Ana, Abdelnour, Carla, Vargas, Liliana, de Antonio, Ester Esteban, López-Cuevas, Rogelio, Tartari, Juan Pablo, Alarcón-Martín, Emilio, Tárraga, Lluís, Ruiz, Agustín, Boada, Mercè, and Valero, Sergi
- Subjects
CONFIRMATORY factor analysis ,EXPLORATORY factor analysis ,MILD cognitive impairment ,FACTOR structure ,NEUROPSYCHOLOGICAL tests ,CLINICAL neuropsychology ,PERCEIVED Stress Scale ,MEMORY ,MEDICAL consultation ,POCKET computers ,ATTENTION ,TELEMEDICINE - Abstract
Background: Over the last decade, teleneuropsychology has increased substantially. There is a need for valid neuropsychological batteries to be administered home-to-home. Since 2006, the neuropsychological battery of Fundació ACE (NBACE) has been administered face-to-face in our clinical settings. Recently, we adapted the NBACE for teleneuropsychology use to be administered home-to-home (NBACEtn).Objective: The aims of the present study are: 1) to determine the home-to-home NBACE equivalence compared to its original face-to-face version; and 2) to examine home-to-home NBACE discriminant capacity by differentiating among cognitively healthy, mild cognitive impairment, or mild dementia subjects and comparing it with the face-to-face version.Methods: Data from 338 individuals assessed home-to-home (NBACEtn) were contrasted with 7,990 participants assessed with its face-to-face version (NBACE). Exploratory and confirmatory factorial structure, and invariance analysis of the two versions of the battery were performed.Results: Exploratory and confirmatory factor analysis supported the four-factor model (attention, memory, executive, and visuospatial/constructional functions). Configural, metric, and scalar measurement invariance was found between home-to-home and face-to-face NBACE versions. Significant differences in most of the neuropsychological variables assessed were observed between the three clinical groups in both versions of administration. No differences were found between the technological devices used by participants (computer or tablet and mobile devices).Conclusion: For the first time, invariance analysis findings were addressed by determining a teleneuropsychological battery's equivalence in comparison with its face-to-face version. This study amplifies the neuropsychological assessment's applicability using a home-to-home format, maintaining the original measure's structure, interpretability, and discriminant capacity. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative.
- Author
-
Marquié, Marta, Valero, Sergi, Castilla-Marti, Miguel, Martínez, Joan, Rodríguez-Gómez, Octavio, Sanabria, Ángela, Tartari, Juan Pablo, Monté-Rubio, Gemma C., Sotolongo-Grau, Oscar, Alegret, Montserrat, Pérez-Cordón, Alba, Roberto, Natalia, de Rojas, Itziar, Moreno-Grau, Sonia, Montrreal, Laura, Hernández, Isabel, Rosende-Roca, Maitee, Mauleón, Ana, Vargas, Liliana, and Abdelnour, Carla
- Subjects
- *
VISUAL fields , *POSITRON emission tomography , *OPTICAL coherence tomography , *MILD cognitive impairment , *ALZHEIMER'S patients , *THICKNESS measurement - Abstract
Background: Optical coherence tomography (OCT) of the retina is a fast and easily accessible tool for the quantification of retinal structural measurements. Multiple studies show that patients with Alzheimer's disease (AD) exhibit thinning in several retinal layers compared to age-matched controls. Subjective cognitive decline (SCD) has been proposed as a risk factor for progression to AD. There is little data about retinal changes in preclinical AD and their correlation with amyloid-β (Aβ) uptake. Aims: We investigated the association of retinal thickness quantified by OCT with Aβ accumulation and conversion to mild cognitive impairment (MCI) over 24 months in individuals with SCD. Methods: One hundred twenty-nine individuals with SCD enrolled in Fundació ACE Healthy Brain Initiative underwent comprehensive neuropsychological testing, OCT scan of the retina and florbetaben (FBB) positron emission tomography (PET) at baseline (v0) and after 24 months (v2). We assessed the association of sixteen retinal thickness measurements at baseline with FBB-PET status (+/−) and global standardize uptake value ratio (SUVR) as a continuous measure at v0 and v2 and their predictive value on clinical status change (conversion to mild cognitive impairment (MCI)) at v2. Results: Mean age of the sample was 64.72 ± 7.27 years; 62.8% were females. Fifteen participants were classified as FBB-PET+ at baseline and 22 at v2. Every 1 μm of increased thickness in the inner nasal macular region conferred 8% and 6% higher probability of presenting a FBB-PET+ status at v0 (OR = 1.08, 95% CI = 1.02–1.14, p = 0.007) and v2 (OR = 1.06, 95% CI = 1.02–1.11, p = 0.004), respectively. Inner nasal macular thickness also positively correlated with global SUVR (at v0: β = 0.23, p = 0.004; at v2: β = 0.26, p = 0.001). No retinal measurements were associated to conversion to MCI over 24 months. Conclusions: Subtle retinal thickness changes in the macular region are already present in SCD and correlate with Aβ uptake. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer's disease.
- Author
-
Alegret, Montserrat, Muñoz, Nathalia, Roberto, Natalia, Rentz, Dorene M., Valero, Sergi, Gil, Silvia, Marquié, Marta, Hernández, Isabel, Riveros, Catalina, Sanabria, Angela, Perez-Cordon, Alba, Espinosa, Ana, Ortega, Gemma, Mauleón, Ana, Abdelnour, Carla, Rosende-Roca, Maitee, Papp, Kathryn V., Orellana, Adela, Benaque, Alba, and Tarraga, Lluís
- Subjects
ALZHEIMER'S disease ,COGNITION disorders ,AUTOMATIC speech recognition ,MILD cognitive impairment ,EPISODIC memory - Abstract
Background: Computerized neuropsychological tests for early detection of Alzheimer's disease (AD) have attracted increasing interest. Memory for faces and proper names is a complex task because its association is arbitrary. It implicates associative occipito-temporal cerebral regions, which are disrupted in AD. The short form of the Face-Name Associative Memory Exam (FNAME-12), developed to detect preclinical and prodromal AD, asks individuals to learn the names and occupations associated with 12 faces. The current work advances this field by using voice recognition and touchscreen response format. The purpose of this study is to create the first self-administered episodic memory test, FACEmemory®, by adapting the FNAME-12 for tablet use with voice recognition, touchscreen answers, and automatic scoring. The test was minimally supervised by a psychologist to avoid technological problems during execution and scored manually to assess the reliability of the automatic scoring. The aims of the present study were (1) to determine whether FACEmemory® is a sensitive tool for the detection of cognitive impairment, (2) to examine whether performances on FACEmemory® are correlated with those on the S-FNAME (paper-and-pencil version with 16 images), and (3) to determine whether performances on FACEmemory® are related to AD biomarkers in the cerebrospinal fluid (CSF) (Aβ42, p-tau, and Aβ42/p-tau ratio). Methods: FACEmemory® was completed by 154 cognitively healthy (CH) individuals and 122 subjects with mild cognitive impairment, of whom 61 were non-amnestic (naMCI) and 61 amnestic (aMCI). A subsample of 65 individuals completed the S-FNAME, and 65 subjects received lumbar punctures. Results: Performance on FACEmemory® was progressively worse from CH to the naMCI and aMCI groups. A cutoff of 31.5 in total FACEmemory® obtained 80.5% and 80.3% sensitivity and specificity values, respectively, for discriminating between CH and aMCI. Automatically corrected FACEmemory® scores were highly correlated with the manually corrected ones. FACEmemory® scores and AD CSF biomarker levels were significantly correlated as well, mainly in the aMCI group. Conclusions: FACEmemory® may be a promising memory prescreening tool for detecting subtle memory deficits related to AD. Our findings suggest FACEmemory® performance provides a useful gradation of impairment from normal aging to aMCI, and it is related to CSF AD biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Exploring Genetic Associations of Alzheimer's Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes.
- Author
-
Espinosa, Ana, Hernández-Olasagarre, Begoña, Moreno-Grau, Sonia, Kleineidam, Luca, Heilmann-Heimbach, Stefanie, Hernández, Isabel, Wolfsgruber, Steffen, Wagner, Holger, Rosende-Roca, Maitée, Mauleón, Ana, Vargas, Liliana, Lafuente, Asunción, Rodríguez-Gómez, Octavio, Abdelnour, Carla, Gil, Silvia, Marquié, Marta, Santos-Santos, Miguel A., Sanabria, Ángela, Ortega, Gemma, and Monté-Rubio, Gemma
- Published
- 2018
- Full Text
- View/download PDF
19. Author Correction: Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic.
- Author
-
Valero, Sergi, Marquié, Marta, De Rojas, Itziar, Espinosa, Ana, Moreno‑Grau, Sonia, Orellana, Adelina, Montrreal, Laura, Hernández, Isabel, Mauleón, Ana, Rosende‑Roca, Maiteé, Alegret, Montse, Pérez‑Cordón, Alba, Ortega, Gemma, Roberto, Natalia, Sanabria, Angela, Abdelnour, Carla, Gil, Silvia, Tartari, Juan Pablo, Vargas, Liliana, and Antonio, Ester Esteban‑De
- Subjects
- *
NEUROBEHAVIORAL disorders , *MILD cognitive impairment - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.